These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27198868)

  • 41. Antibiotic resistance--problems, progress, and prospects.
    Nathan C; Cars O
    N Engl J Med; 2014 Nov; 371(19):1761-3. PubMed ID: 25271470
    [No Abstract]   [Full Text] [Related]  

  • 42. Companies to reduce antimicrobial availability.
    Cima G
    J Am Vet Med Assoc; 2014 May; 244(10):1118. PubMed ID: 24908705
    [No Abstract]   [Full Text] [Related]  

  • 43. Rewarding innovation in drug discovery.
    Lopes G
    Health Aff (Millwood); 2009; 28(3):922-3. PubMed ID: 19414906
    [No Abstract]   [Full Text] [Related]  

  • 44. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
    Brogan DM; Mossialos E
    Soc Sci Med; 2016 Feb; 151():167-72. PubMed ID: 26808335
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Busting the billion-dollar myth: how to slash the cost of drug development.
    Maxmen A
    Nature; 2016 Aug; 536(7617):388-90. PubMed ID: 27558048
    [No Abstract]   [Full Text] [Related]  

  • 46. Learning from our mistakes: using key opportunities to remove the perverse incentives that help drive antibiotic resistance.
    Edwards SE; Morel CM
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):685-692. PubMed ID: 31847613
    [No Abstract]   [Full Text] [Related]  

  • 47. A framework for global surveillance of antibiotic resistance.
    Grundmann H; Klugman KP; Walsh T; Ramon-Pardo P; Sigauque B; Khan W; Laxminarayan R; Heddini A; Stelling J
    Drug Resist Updat; 2011 Apr; 14(2):79-87. PubMed ID: 21482177
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibiotic development pipeline runs dry. New drugs to fight resistant organisms are not being developed, experts say.
    Nelson R
    Lancet; 2003 Nov; 362(9397):1726-7. PubMed ID: 14655659
    [No Abstract]   [Full Text] [Related]  

  • 49. Repairing the broken market for antibiotic innovation.
    Outterson K; Powers JH; Daniel GW; McClellan MB
    Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibiotic cycling and marketing into the 21st century: a perspective from the pharmaceutical industry.
    Lavin BS
    Infect Control Hosp Epidemiol; 2000 Jan; 21(1 Suppl):S32-5. PubMed ID: 10654633
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Introduction: pharmaceutical innovation: law & the public's health.
    Outterson K
    J Law Med Ethics; 2009; 37(2):173-5. PubMed ID: 19493064
    [No Abstract]   [Full Text] [Related]  

  • 52. R&D: Antibiotic partners promote discovery.
    Bakken JS
    Nature; 2016 Sep; 537(7619):167. PubMed ID: 27604939
    [No Abstract]   [Full Text] [Related]  

  • 53. 'Tax pharma companies if they fail to act on AMR', says Review chief Lord O'Neill.
    Vet Rec; 2018 Jun; 182(26):728. PubMed ID: 29954991
    [No Abstract]   [Full Text] [Related]  

  • 54. Society must seize control of the antibiotics crisis.
    Amábile-Cuevas C
    Nature; 2016 May; 533(7604):439. PubMed ID: 27225081
    [No Abstract]   [Full Text] [Related]  

  • 55. Preclinical antibiotic pipeline gets a pick-me-up.
    Mullard A
    Nat Rev Drug Discov; 2017 Oct; 16(11):741-742. PubMed ID: 29081528
    [No Abstract]   [Full Text] [Related]  

  • 56. A new prize system for drug innovation.
    Gandjour A; Chernyak N
    Health Policy; 2011 Oct; 102(2-3):170-7. PubMed ID: 21724290
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The $2.6 billion pill--methodologic and policy considerations.
    Avorn J
    N Engl J Med; 2015 May; 372(20):1877-9. PubMed ID: 25970049
    [No Abstract]   [Full Text] [Related]  

  • 58. When the price of the blood-pressure drug Nitropress leaped from $215 to $881 last year, an increase of 310%, it triggered public outrage: What's behind the gouging?
    Edwards HS
    Time; 2016 May; 187(20):38-43. PubMed ID: 27491134
    [No Abstract]   [Full Text] [Related]  

  • 59. R&D transformation and value-based innovation.
    Epstein RS
    J Comp Eff Res; 2012 Jan; 1(1 Suppl):1-2. PubMed ID: 24237315
    [No Abstract]   [Full Text] [Related]  

  • 60. Antibiotic development: a victim of market forces?
    Tillotson GS
    IDrugs; 2008 May; 11(5):340-6. PubMed ID: 18465675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.